COMMUNIQUÉS West-GlobeNewswire

ProQR Announces Clearance of IND to Start Clinical Trial of QR-421a in Usher Syndrome Type 2 Patients

04/12/2018 - 13:00

LEIDEN, Netherlands & CAMBRIDGE, Mass., Dec. 04, 2018 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq:PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines for the [...]

Emerald Joint Venture Receives Licenses from Health Canada to Sell Proprietary Products Supporting the Endocannabinoid System

04/12/2018 - 13:00

Endo Brain recently awarded 2018 SupplySide Editor’s Choice Award for Brain Health Planned mid-2019 product launch will open natural health product, grocery, and pharmacy store channels to Emerald non-cannabis product [...]

Pluristem Therapeutics Enters into Cell Thawing Device License Agreement with Chart Industries, Inc.

04/12/2018 - 13:00

HAIFA, Israel, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (Nasdaq:PSTI) (TASE:PSTI), a leading regenerative medicine company developing novel placenta-based cell therapy products, today announced that [...]

Preliminary Results from Randomized Phase 2 Trial Demonstrate Trilaciclib Improved Progression-Free Survival in Combination with Chemotherapy in Patients with Metastatic Triple-Negative Breast Cancer

04/12/2018 - 12:55

Patients on trilaciclib received more chemotherapy cycles than those in the control arm Trilaciclib showed multi-lineage myelopreservation benefits when adjusting for longer duration of treatment Safety profile [...]

RavenQuest Begins Cannabis Sales

04/12/2018 - 12:00

VANCOUVER, British Columbia, Dec. 04, 2018 (GLOBE NEWSWIRE) -- RavenQuest BioMed Inc. (the “Company” or “RavenQuest”) – (CSE: RQB OTCQB: RVVQF Frankfurt: 1IT ) is pleased to announce that it is concluding its first [...]

INSYS Therapeutics Presents New Clinical Data from Long-Term Safety Study of CBD Oral Solution in Refractory Pediatric Epilepsy

04/12/2018 - 12:00

PHOENIX, Dec. 04, 2018 (GLOBE NEWSWIRE) -- Pharmaceutical-grade cannabidiol (CBD) oral solution made by INSYS Therapeutics, Inc. (NASDAQ: INSY), a leader in the development, manufacture and commercialization of [...]

Transactions in relation to share buyback program

04/12/2018 - 11:15

Acting under its share buyback authorization, the GN Store Nord Board of Directors initiated a share buyback program on May 2, 2018, in accordance with article 5 of the regulation (EU) no. 596/2014 of 16 April 2014 on [...]

Lundbeck announces retirement of Anders Gersel Pedersen, EVP and Head of Research and Development

04/12/2018 - 09:38

Valby, Denmark, 4 December 2018 - H. Lundbeck A/S (Lundbeck) today announced that Anders Gersel Pedersen, Executive Vice President and Head of Research and Development (R&D), will retire after 19 years with the [...]

Rule 2.9 Announcement

04/12/2018 - 08:00

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. 4 December 2018 [...]

Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China

04/12/2018 - 07:00

SAN DIEGO and SHENZHEN, China, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a financing, with [...]

Updated Interim Results from Ongoing Phase 2a Study of Portola Pharmaceuticals’ Oral Syk/JAK Inhibitor Cerdulatinib Continues to Demonstrate Clinical Responses in Heavily Pre-Treated T-Cell Malignancies

04/12/2018 - 03:15

– Early Signs of Durable Response Across Patients with Relapsed/Refractory PTCL – – 50 Percent Complete Response Rate Observed in Patients with AITL – – Rapid and Significant Reduction in Itching Among Patients with [...]

Poseida Therapeutics Provides Update on Phase 1 Study of P-BCMA-101 CAR-T Product Candidate at the 2018 American Society of Hematology Annual Meeting

04/12/2018 - 03:15

P-BCMA-101 showed a 100% ORR with patients achieving rapid and deep responses with no CRS or neurotoxicity observed at the planned Phase 2 dose SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Poseida Therapeutics Inc., a [...]

Atara Biotherapeutics Announces Next-Generation CAR T Discoveries and Positive T-Cell Immunotherapy Results in Patients with EBV+ PTLD Involving the CNS at 60th American Society of Hematology (ASH) Annual Meeting

04/12/2018 - 02:45

Moffitt Cancer Center collaborators described next-generation chimeric antigen receptor T-cell (CAR T) technology that increases T cell persistence and decreases exhaustion Memorial Sloan Kettering collaborators [...]

Allogene Therapeutics and Servier Present Pooled Data from Phase 1 Trials of Allogeneic UCART19 in Relapsed/Refractory Acute Lymphoblastic Leukemia

04/12/2018 - 01:45

82 percent of Patients Achieved a Complete Remission when Lymphodepletion Regimen Included an anti-CD52 Monoclonal Antibody (mAb) Safety Profile of UCART19 Appears Manageable with No Evidence of Moderate or Severe Graft [...]

Driven Inc. to Present at the 11th Annual LD Micro Main Event

04/12/2018 - 01:00

SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Driven Inc. (OTC: RBOS), a cannabis delivery service, announced today that they will be presenting at the 11th Annual LD Micro Main Event. The conference is being held on [...]

REVA Announces First Implant of the Fantom Encore Bioresorbable Scaffold in Italy

04/12/2018 - 00:44

SAN DIEGO, Dec. 03, 2018 (GLOBE NEWSWIRE) -- REVA Medical, Inc. (ASX: RVA) (“REVA” Or The “Company”), a leader in bioresorbable polymer technologies for vascular applications, announced the first implant of its recently [...]

Phase 1 Expansion Cohort Oral Presentations for Flotetuzumab, MacroGenics’ CD123 x CD3 DART® Molecule, in Relapsed/Refractory Acute Myeloid Leukemia Presented at 60th ASH Annual Meeting

04/12/2018 - 00:30

Flotetuzumab demonstrated 29.4% complete response rate in evaluable primary refractory AML patients Translational studies suggest potential strategy for biomarker-based patient selection ROCKVILLE, Md., Dec. 03, 2018 ( [...]

National Rheumatology and Psoriasis Organizations Release Joint Guideline for Treating Psoriatic Arthritis

03/12/2018 - 23:04

Recommends Treat-to-Target Approach, First-Line Use of TNFi Biologics, and Smoking Cessation Atlanta, Dec. 03, 2018 (GLOBE NEWSWIRE) -- The American College of Rheumatology (ACR) and National Psoriasis Foundation (NPF) [...]

Biocartis Group NV: Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla(TM) Oncotype DX Genomic Prostate Score® Test

03/12/2018 - 22:31

PRESS RELEASE: 3 December 2018, 22:30 CET/16:30 EST Genomic Health and Biocartis Expand Collaboration to Urology with the Development of an Idylla(TM) Oncotype DX Genomic Prostate Score ® Test REDWOOD CITY, Calif., [...]